Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disorders Tryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics”
Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas Tryp has partnered with the University of Florida to conduct a Phase … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders”
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has provided a corporate update regarding its cannabis, functional mushroom and psilocybin business operations. The update notes that, in spite of COVID-19, its Pemberton, British Columbia facility is fully operational … Continue reading “NetworkNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Releases Corporate Update”
Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training”
Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways The company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas) Through its PFN(TM) program, the company is … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs, has reported its interim financial results and business highlights for the three- and six-month periods ended Feb. 28, 2021. Highlights of the report include … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Second-Quarter 2021 Financial Numbers”
Investment Considerations Tryp Therapeutics is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. The company is targeting diseases with few existing treatments options for patients that represents more than $12 billion in annual sales potential. Tryp is initiating multiple Phase 2a clinical trials … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)”
PULL starts production of roughly 50,000 blister pack gummies using Taste-T LLC’s successful proprietary manufacturing system Global CBD gummies market size estimated to grow at CAGR of 31.9% until 2025 PULL estimates $200,000 in revenue from initial batch, plans to produce three additional non-THC SKUs with varying levels of ultra-high potency CBD Pure Extracts Technologies … Continue reading “Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Retail Business to Bloom This Spring With Production of 50,000 Blister Packs”
PsyBio (TSXV: PSYB), a biotechnology company pioneering the next generation of targeted psychoactive medications, today announced that it has amended its master sponsored agreement with Miami University based in Oxford, Ohio. The amended agreement extends and expands the research efforts of the laboratory of Dr. J. Andrew Jones in the Department of Chemical, Paper and … Continue reading “NetworkNewsBreaks – PsyBio Therapeutics Corp. (TSXV: PSYB) Expands Collaboration with Miami University to Expedite FDA IND Submission”
NetworkNewsWire Editorial Coverage: The push for psychedelic medicine is surging across North America and around the world. Scientific evidence supports the life-changing impact this safe and natural alternative has in treating mental illness of all types. New research from a number of organizations, including Johns Hopkins in Baltimore and Imperial College in London, which revealed … Continue reading “Science Drives Surging Interest in Psychedelic Therapeutics”
